Apo-Methylphenidate CR Product Monograph

RECENT MAJOR LABEL CHANGES

N/A

TABLE OF CONTENTS

Certain sections or subsections that are not applicable at the time of the preparation of the most recent authorized product monograph are not listed.

RECENT MAJOR LABEL CHANGES .......................................................................................... 2

TABLE OF CONTENTS ........................................................................................................... 2

PART I: HEALTH PROFESSIONAL INFORMATION .................................................................... 4

1 INDICATIONS ............................................................................................................ 4

1.1 Pediatrics ............................................................................................................... 4

1.2 Geriatrics ............................................................................................................... 4

2 CONTRAINDICATIONS ............................................................................................... 5

3 SERIOUS WARNINGS AND PRECAUTIONS BOX .......................................................... 5

4 DOSAGE AND ADMINISTRATION ............................................................................... 5

4.1 Dosing Considerations .......................................................................................... 5

4.2 Recommended Dose and Dosage Adjustment ..................................................... 6

4.4 Administration ...................................................................................................... 7

4.5 Missed Dose .......................................................................................................... 8

5 OVERDOSAGE ........................................................................................................... 8

6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING ............................... 9

7 WARNINGS AND PRECAUTIONS .............................................................................. 10

7.1 Special Populations ............................................................................................. 15

7.1.1 Pregnant Women ................................................................................................ 15

7.1.2 Breast-feeding ..................................................................................................... 15

7.1.3 Pediatrics ............................................................................................................. 16

7.1.4 Geriatrics ............................................................................................................. 16

8 ADVERSE REACTIONS .............................................................................................. 16

8.1 Adverse Reaction Overview ................................................................................ 16

8.2 Clinical Trial Adverse Reactions .......................................................................... 16

8.2.1 Clinical Trial Adverse Reactions – Pediatrics....................................................... 19

8.3 Less Common Clinical Trial Adverse Reactions ................................................... 23

8.3.1 Less Common Clinical Trial Adverse Reactions – Pediatrics ............................... 23

8.5 Post-Market Adverse Reactions .......................................................................... 23

9 DRUG INTERACTIONS ............................................................................................. 24

9.1 Serious Drug Interactions ................................................................................... 24

9.2 Drug Interactions Overview ................................................................................ 24

9.3 Drug-Behavioural Interactions ............................................................................ 24

9.4 Drug-Drug Interactions ....................................................................................... 25

9.5 Drug-Food Interactions ....................................................................................... 26

9.6 Drug-Herb Interactions ....................................................................................... 26

9.7 Drug-Laboratory Test Interactions...................................................................... 26

10 CLINICAL PHARMACOLOGY ..................................................................................... 26

10.1 Mechanism of Action .......................................................................................... 26

10.2 Pharmacodynamics ............................................................................................. 27

10.3 Pharmacokinetics ................................................................................................ 27

11 STORAGE, STABILITY AND DISPOSAL ....................................................................... 29

12 SPECIAL HANDLING INSTRUCTIONS ......................................................................... 29

PART II: SCIENTIFIC INFORMATION .................................................................................... 30

13 PHARMACEUTICAL INFORMATION .......................................................................... 30

14 CLINICAL TRIALS ..................................................................................................... 30

14.1 Efficacy and Safety studies ................................................................................. 30

Trial Design and Study Demographics ............................................................................ 30

14.2 Study Results ....................................................................................................... 32

14.3 Comparative Bioavailability Studies ................................................................... 36

15 MICROBIOLOGY ...................................................................................................... 37

16 NON-CLINICAL TOXICOLOGY ................................................................................... 37

17 SUPPORTING PRODUCT MONOGRAPHS .................................................................. 38

PATIENT MEDICATION INFORMATION ............................................................................... 39

PART I: HEALTH PROFESSIONAL INFORMATION

1 INDICATIONS

APO-METHYLPHENIDATE CR (methylphenidate hydrochloride controlled-release capsules) is indicated for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in:

• Children (6 to 11 years of age)
• Adolescents (12 to 18 years of age)
• Adults (>18 years of age)

Long-Term Use

The effectiveness of methylphenidate hydrochloride controlled-release capsules for long-term use, i.e. for more than 4 weeks, has not been systematically evaluated in placebo-controlled trials. The health professional who elects to use APO-METHYLPHENIDATE CR for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see 4.1 Dosing Considerations).

Need for Comprehensive Treatment Program

APO-METHYLPHENIDATE CR is indicated as an integral part of a total treatment program for ADHD that may include other measures (i.e., psychological, educational, and/or social) for patients with this syndrome. Drug treatment may not be indicated for all patients with this syndrome. Drug treatment is not intended for use in the patient who exhibits symptoms secondary to environmental factors and/or other primary psychiatric disorders, including psychosis. Appropriate educational placement is essential in children and adolescents with this diagnosis and psychosocial intervention is often helpful. When remedial measures alone are insufficient, the decision to prescribe drug treatment will depend upon the health professional’s assessment of the chronicity and severity of the patient’s symptoms.

1.1 Pediatrics

Pediatrics (<6 years of age): APO-METHYLPHENIDATE CR should not be used in children under 6 years of age. No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use in children under 6 years of age (see 4.2 Recommended Dose and Dosage Adjustment).

Pediatrics (6 to 18 years of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of methylphenidate hydrochloride controlled-release capsules in pediatric patients (6 years of age and older) has been established. Therefore, Health Canada has authorized an indication for pediatric use (see 4.2 Recommended Dose and Dosage Adjustment).

1.2 Geriatrics

Geriatrics (>65 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for geriatric use.

2 CONTRAINDICATIONS

APO-METHYLPHENIDATE CR is contraindicated in:

• Patients who are hypersensitive to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container. For a complete listing, see 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING.
• Anxiety, tension
• Agitation
• Thyrotoxicosis
• Advanced arteriosclerosis
• Symptomatic cardiovascular disease
• Moderate to severe hypertension
• Glaucoma
• History of drug abuse
• Patients with motor tics or with a family history or diagnosis of Tourette’s syndrome (verbal tics) (see 7 WARNINGS AND PRECAUTIONS, Neurologic).
• Co-Administration of Monoamine Oxidase Inhibitors (MAOIs): During treatment with monoamine oxidase inhibitors and within a minimum of 14 days following discontinuation of a monoamine oxidase inhibitor (hypertensive crises may result) (see 9.4 Drug-Drug Interactions, Monoamine Oxidase Inhibitors; 9.1 Serious Drug Interactions).

3 SERIOUS WARNINGS AND PRECAUTIONS BOX

Serious Warnings and Precautions

• Drug Dependence – Like other stimulants, APO-METHYLPHENIDATE CR has the potential to be abused, leading to dependence and tolerance (see 7 WARNINGS AND PRECAUTIONS, Dependence/Tolerance).

4 DOSAGE AND ADMINISTRATION

4.1 Dosing Considerations

• APO-METHYLPHENIDATE CR should be administered starting at the lowest possible dose. Dosage should, then, be individually and slowly adjusted, to the lowest effective dosage since individual patient’s response to APO-METHYLPHENIDATE CR varies widely. If paradoxical aggravation of symptoms or other adverse effects occur, reduce dosage,

  • or if necessary, discontinue the drug.
• APO-METHYLPHENIDATE CR should be periodically discontinued to assess the patient’s condition. Improvement may be sustained when the drug is either temporarily or permanently discontinued.

• Patients currently receiving immediate-release formulations of methylphenidate may be converted to the next lower strength, based on the total methylphenidate daily dose.

  Dosage should, then, be individually and slowly adjusted, to the lowest effective dosage.

• The maximum daily dose should not exceed 60 mg for children and adolescents (6 to 18 years) or 80 mg for adults (>18 years).
• Assessing Cardiovascular Status in Patients being Treated with Sympathomimetic Medications

APO-METHYLPHENIDATE CR should not be used in patients with symptomatic cardiovascular disease and should generally not be used in patients with known structural cardiac abnormalities (see 2 CONTRAINDICATIONS and 7 WARNINGS AND PRECAUTIONS, Cardiovascular).

Theoretically, there exists a pharmacological potential for all ADHD drugs to increase the risk of sudden/cardiac death. Although confirmation of an incremental risk for adverse cardiac events arising from treatment with ADHD medications is lacking, prescribers should consider this potential risk.

All drugs with sympathomimetic effects prescribed in the management of ADHD should be used with caution in patients who: a) are involved in strenuous exercise or activities, b) use other stimulants, or c) have a family history of sudden/cardiac death.

Prior to the initiation of treatment, a personal and family history (including assessment for a family history sudden death or ventricular arrhythmia) and physical exam should be obtained to assess for the presence of cardiac disease. In patients with relevant risk factors and based on the clinician’s judgement, further cardiovascular evaluation may be considered (e.g., electrocardiogram and echocardiogram). Patients who develop symptoms such as exertional chest pain, unexplained syncope, or other symptoms suggestive of cardiac disease during ADHD treatment should undergo a prompt cardiac evaluation. Patients who are considered to need extended treatment with APO-METHYLPHENIDATE CR should undergo periodic evaluation of their cardiovascular status (see 7 WARNINGS AND PRECAUTIONS, Cardiovascular).

4.2 Recommended Dose and Dosage Adjustment

• Pediatrics (<6 years of age): Health Canada has not authorized an indication for pediatric use in patients less than 6 years of age (see 1.1 Pediatrics).

• Pediatrics (6 to 18 years of age): APO-METHYLPHENIDATE CR is to be administered as a single daily dose in the morning. The usual initial dose should be 10 to 20 mg/day orally.

  • The total daily dose may be adjusted in weekly increments of 10 mg/day up to a maximum of 60 mg/day. Patients should establish a routine pattern with regard to meals (see 4.4 Administration).

In some children, higher doses (maximum 1 mg/kg/day) may be necessary and in such cases, careful monitoring for adverse events should be implemented. If adverse events occur, the dosage should be reduced or, if necessary, the drug should be discontinued. If improvement is not observed after appropriate dosage adjustment the drug should be discontinued.

• Adults (>18 years of age): APO-METHYLPHENIDATE CR is to be administered as a single daily dose in the morning. The usual initial dose should be 10 to 20 mg/day orally. The daily dose should be titrated weekly, in increments of 10 mg, according to individual response, up to a maximum dose of 80 mg/day. Patients should establish a routine pattern with regard to meals (see 4.4 Administration).
• Geriatrics (>65 years of age): Health Canada has not authorized an indication for geriatric use (see 1.2 Geriatrics).
• Patients with Hepatic Insufficiency: There is no experience with the use of methylphenidate in patients with hepatic insufficiency.
• Patients with Renal Insufficiency: There is very limited experience with the use of methylphenidate in patients with renal insufficiency. Renal clearance is not significant for methylphenidate elimination, but the main methylphenidate metabolite, inactive ritalinic acid, is predominantly (80%) cleared through the urine.
• Long-term use: There is no evidence available from controlled trials to indicate how long the patient with ADHD should be treated with methylphenidate hydrochloride controlled-release capsules. It is generally agreed that pharmacological treatment of ADHD may be needed for extended periods. The physician who elects to use APO-METHYLPHENIDATE CR for extended periods in patients with ADHD should periodically re-evaluate the long-term usefulness of the drug for the individual patient with trials off medication to assess the patient’s functioning without pharmacotherapy.
• Dose reduction and discontinuation: If paradoxical aggravation of symptoms or other adverse effects occur, reduce dosage, or if necessary, discontinue the drug. If little or no improvement is observed after appropriate dosage adjustment over a one-month period, the drug should be discontinued.

4.4 Administration

APO-METHYLPHENIDATE CR capsules should be swallowed whole and must never be crushed or chewed.

For patients unable to swallow the capsule, the capsule may be opened, and the entire contents sprinkled onto a tablespoon of applesauce, ice cream or yogurt. Do not sprinkle in liquids. The entire mixture should be consumed immediately or within 30 minutes without chewing and should be discarded if not consumed. The dose of a single capsule should not be divided. The contents of the entire capsule should be taken, and patients should not take anything less than one capsule per day. Ingestion should be followed by rinsing the mouth with water to ensure that the entire contents are swallowed.

APO-METHYLPHENIDATE CR may be taken with or without food. However, concomitant food intake has variable effects on methylphenidate exposure. Thus, a regular morning routine should be established, with regard to the content and timing of meals, in order to ensure consistent efficacy and safety (see 9.5 Drug-Food Interactions).

4.5 Missed Dose

If a dose of APO-METHYLPHENIDATE CR is missed, the patient should be instructed to take the next dose in the usual amount at the usual time the next morning. Patients should be instructed not to take an afternoon dose and not to double the dose.

5 OVERDOSAGE

Signs and symptoms of acute overdose, resulting principally from overstimulation of the central nervous system and from excessive sympathomimetic effects, may include the following: agitation, cardiac arrhythmias, confusion, convulsions (may be followed by coma), delirium, diarrhea, euphoria, flushing, hallucinations, headache, hyperpyrexia, hyperreflexia, hypertension, muscle twitching, mydriasis and dryness of mucus membranes, nausea, palpitations, rhabdomyolysis, hyperhidrosis, tachycardia, tachypnea, tremors and vomiting.

Treatment consists of providing supportive measures. The patient must be protected against self-injury and against external stimuli that would exacerbate overstimulation already present. Do not induce vomiting pre-hospital due to the risk of abrupt onset of seizures. Intensive care must be provided to maintain adequate circulation and respiratory exchange. External cooling procedures may be required to reduce hyperpyrexia. Efficacy of peritoneal dialysis or extracorporeal hemodialysis for methylphenidate overdosage has not been established.

The controlled release of methylphenidate from APO-METHYLPHENIDATE CR capsules should be considered when treating patients with overdose.

Alcohol may induce the production of methylphenidate. The amount of methylphenidate production is proportional to the blood alcohol concentration (see 9.3 Drug-Behavioural Interactions).

As with the management of all overdosage, the possibility of multiple drug ingestion, including alcohol, should be considered.

For the most recent information in the management of a suspected drug overdose, contact your regional poison control centre or Health Canada’s toll-free number, 1-844 POISON-X (1-844-764-7669).

6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING

Table 1 – Dosage Forms, Strengths, Composition and Packaging

APO-METHYLPHENIDATE CR is available in capsules.

APO-METHYLPHENIDATE CR 10 mg: Hard gelatin capsule with white, opaque body and light turquoise blue, opaque cap. Imprinted “APO M10” in black ink. White to off-white pellet fill.

APO-METHYLPHENIDATE CR 15 mg: Hard gelatin capsule with white, opaque body and orange, opaque cap. Imprinted "APO M15" in black ink. White to off-white pellet fill.

APO-METHYLPHENIDATE CR 20 mg: Hard gelatin capsule with white, opaque body and yellow, opaque cap. Imprinted "APO M20" in black ink. White to off-white pellet fill.

APO-METHYLPHENIDATE CR 30 mg: Hard gelatin capsule with white, opaque body and blue violet, opaque cap. Imprinted "APO M30" in black ink. White to off-white pellet fill.

APO-METHYLPHENIDATE CR 40 mg: Hard gelatin capsule with white, opaque body and pink, opaque cap. Imprinted "APO M40" in black ink. White to off-white pellet fill.

APO-METHYLPHENIDATE CR 50 mg: Hard gelatin capsule with white, opaque body and light green, opaque cap. Imprinted "APO M50" in black ink. White to off-white pellet fill.

APO-METHYLPHENIDATE CR 60 mg: Hard gelatin capsule with white, opaque body and grey, opaque cap. Imprinted "APO M60" in black ink. White to off-white pellet fill.

APO-METHYLPHENIDATE CR 80 mg: Hard gelatin capsule with white, opaque body and orange, opaque cap. Imprinted "APO M80" in black ink. White to off-white pellet fill.

APO-METHYLPHENIDATE CR is supplied in the following presentations:

• bottles of 30 capsules for 10, 15, 20, 30, 40, 50, 60 and 80 mg strengths.

7 WARNINGS AND PRECAUTIONS

Please see 3 SERIOUS WARNINGS AND PRECAUTIONS BOX.

General

Drug treatment is not indicated in all cases of ADHD and should be considered only in light of the complete history and evaluation. The decision to prescribe APO-METHYLPHENIDATE CR should depend on the health professional’s assessment of the chronicity and severity of the patient’s symptoms and their appropriateness for his/her age. Treatment should not depend solely on the presence of one or more abnormal behavioural characteristics. Where these symptoms are associated with acute stress reactions, treatment with methylphenidate is usually not indicated.

Patients with an element of agitation may react adversely; discontinue therapy if necessary.

Fatigue: APO-METHYLPHENIDATE CR should not be used for the prevention or treatment of normal fatigue states.

APO-METHYLPHENIDATE CR is contraindicated with the use of Monoamine Oxidase (MAO) Inhibitors (see 2 CONTRAINDICATIONS, Co-Administration of Monoamine Oxidase Inhibitors (MAOIs)).

Caution should be exercised in prescribing concomitant drugs.

Carcinogenesis and Mutagenesis

See 16 NON-CLINICAL TOXICOLOGY, Genotoxicity and Carcinogenicity for discussion on animal data.

Cardiovascular

• Misuse and Serious Cardiovascular Adverse Events

  The misuse of central nervous system stimulants may cause serious cardiovascular adverse events and sudden death.

• Sudden Death and Pre-existing Structural Cardiac Abnormalities or Other Serious Heart Problems

  • Children and Adolescents: Sudden death has been reported in association with stimulant drugs used for ADHD treatment at usual doses in children and adolescents with structural cardiac abnormalities or other serious cardiac problems. Although some serious heart problems alone carry an increased risk of sudden death, APO-METHYLPHENIDATE CR generally should not be used in children or adolescents with known serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, or other serious cardiac problems that may place them at increased vulnerability to the sympathomimetic effects of a stimulant drug (see 2 CONTRAINDICATIONS).
  • Adults: Sudden death, stroke, and myocardial infarction have been reported in adults taking stimulant drugs at usual doses for ADHD. Although the role of stimulants in these adult cases is also unknown, adults have a greater likelihood than children of having serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems. Adults with such abnormalities should also generally not be treated with stimulant drugs (see 2 CONTRAINDICATIONS).

• Pre-existing Cardiovascular and Cerebral Vascular Conditions

  CNS stimulants should be used with caution in patients with a condition of the cardiovascular or cerebrovascular system, taking into account risk predictors for these conditions. Patients should be screened for pre-existing or underlying cardiovascular or cerebrovascular conditions before initiation of treatment with stimulants and monitored for new conditions of the heart or brain during the course of treatment.

• Hypertension and Other Cardiovascular Conditions

  Hypertension may occur during methylphenidate treatment in some patients. Caution is particularly indicated in treating patients whose underlying medical conditions might be compromised by increases in blood pressure or heart rate, e.g., those with pre-existing hypertension, heart failure, recent myocardial infarction or hyperthyroidism.

  Blood pressure should be monitored at appropriate intervals in patients receiving stimulants, especially in patients with pre-existing conditions that may result in hypertension.

Dependence/Tolerance

Like other stimulants, APO-METHYLPHENIDATE CR has the potential for abuse. APO-METHYLPHENIDATE CR should be given cautiously, particularly to those with a history of drug dependence or alcoholism, because such patients may increase dosage on their own initiative (see 3 SERIOUS WARNINGS AND PRECAUTIONS BOX).

Chronic abuse can lead to marked tolerance and psychological dependence with varying degrees of abnormal behaviour. Frank psychotic episodes can occur, especially with parenteral abuse.

Careful supervision is required during withdrawal from drug use since severe depression may occur. Withdrawal following chronic therapeutic use may unmask symptoms of an underlying disorder that may require follow-up.

Driving and Operating Machinery

Because methylphenidate may affect performance, due caution should be exercised when driving or operating a vehicle or potentially dangerous machinery. Patients should be cautioned accordingly until they are reasonably certain that APO-METHYLPHENIDATE CR does not adversely affect their ability to engage in such activities.

Endocrine and Metabolism

• Long-Term Suppression of Growth

  Sufficient data on the safety of long-term use of methylphenidate in children are not yet available. Although a causal relationship has not been established, suppression of growth (i.e., weight gain, and/or height) has been reported with the long-term use of stimulants in children. Therefore, patients requiring long-term therapy should be carefully monitored.

  Patients who are not growing or gaining weight as expected should have their treatment interrupted.

Monitoring and Laboratory Tests

Periodic laboratory tests are advised during prolonged therapy. The tests should include, but not be limited to, hematological parameters, including complete blood count, differential and platelet counts, and liver enzymes.

Neurologic

• Seizures

  There is some clinical evidence that methylphenidate may lower the convulsive threshold in patients with prior history of seizures, with prior EEG abnormalities in the absence of seizures and, very rarely, in patients with no prior EEG evidence or history of seizures.

  Clinical experience has shown that a small number of patients may experience an increase in seizure frequency when treated with methylphenidate. If seizure frequency rises, the drug should be discontinued.

• Motor and Verbal Tics, and Worsening of Tourette’s Syndrome:

  CNS stimulants, including methylphenidate, have been associated with the onset or exacerbation of motor and verbal tics. Worsening of Tourette’s syndrome has also been reported with other CNS stimulants. It is recommended that the family history be assessed, and that the patient is clinically evaluated for tics or Tourette’s syndrome before initiating methylphenidate. Regular monitoring for the emergence or worsening of tics or Tourette’s syndrome during treatment with methylphenidate is recommended at every dose adjustment and every visit, and treatment discontinued if clinically appropriate (see 2 CONTRAINDICATIONS).

• Serotonin toxicity / Serotonin syndrome

  Serotonin toxicity also known as serotonin syndrome is a potentially life-threatening condition and has been reported with methylphenidate, including methylphenidate controlled-release capsules particularly during combined use with other serotonergic drugs (see 9.4 Drug-Drug Interactions, Serotonergic Drugs).

  Serotonin toxicity is characterised by neuromuscular excitation, autonomic stimulation (e.g. tachycardia, flushing) and altered mental state (e.g., anxiety, agitation, hypomania). In accordance with the Hunter Criteria, serotonin toxicity diagnosis is likely when, in the presence of at least one serotonergic agent, one of the following is observed:

  • Spontaneous clonus
  • Inducible clonus or ocular clonus with agitation or diaphoresis
  • Tremor and hyperreflexia
  • Hypertonia and body temperature >38°C and ocular clonus or inducible clonus.

If concomitant treatment with APO-METHYLPHENIDATE CR and other serotonergic agents is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see 9.4 Drug-Drug Interactions, Serotonin toxicity/Serotonin syndrome). If serotonin toxicity is suspected, discontinuation of the serotonergic agents should be considered.

Ophthalmologic

Visual Disturbance

Symptoms of visual disturbances have been encountered in rare cases. Difficulties with accommodation and blurring of vision have been reported (see 8 ADVERSE REACTIONS).

Psychiatric

• Suicidal Behaviour and Ideation

  There have been post-marketing reports of suicide-related events in patients treated with ADHD drugs, including cases of ideation, attempts, and very rarely, completed suicide. The mechanism of this risk is not known. ADHD and its related co-morbidities may be associated with increased risk of suicidal ideation and/or behaviour. Therefore, it is recommended that patients treated with ADHD drugs be monitored for signs of suicide-related behaviour, including at dose initiation/optimization and drug discontinuation. Patients should be encouraged to report any distressing thoughts or feelings at any time to their healthcare professional.

  Patients with emergent suicidal ideation and behaviour should be evaluated immediately. The health professional should initiate appropriate treatment of the underlying psychiatric condition and consider a possible change in the ADHD treatment regimen (see 8.5 Post-Market Adverse Reactions).

• Aggression, Anxiety and Agitation

  Aggressive behaviour or hostility, marked anxiety or agitation are often observed in children and adolescents with ADHD and have been reported in clinical trials and the post-marketing experience of some medications indicated for the treatment of ADHD. Although there is no systematic evidence that stimulants cause aggressive behaviour or hostility, patients beginning treatment for ADHD should be monitored for the appearance of or worsening of aggressive behaviour or hostility, marked anxiety or agitation.

• Emergence of New Psychotic or Manic Symptoms

  Treatment emergent psychotic or manic symptoms, e.g., hallucinations, delusional thinking, or mania, in children and adolescents without a prior history of psychotic illness or mania can be caused by stimulants at usual doses. If such symptoms occur, consideration should be given to a possible causal role of the stimulant, and discontinuation of treatment may be appropriate. In a pooled analysis of multiple short-term, placebo-controlled studies, such symptoms occurred in about 0.1% (4 patients with events out of 3482 exposed to methylphenidate or amphetamine for several weeks at usual doses) of stimulant-treated patients compared to 0 in placebo-treated patients.

• Screening Patients for Bipolar Disorder

  Particular care should be taken in using stimulants to treat ADHD in patients with comorbid bipolar disorder because of concern for possible induction of a mixed/manic episode in such patients. Prior to initiating treatment with a stimulant, patients with comorbid depressive symptoms should be adequately screened to determine if they are at risk for bipolar disorder; such screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder and depression.

• Pre-Existing Psychosis

  Administration of stimulants may exacerbate symptoms of behaviour disturbance and thought disorder in patients with a pre-existing psychotic disorder.

• Depression

  APO-METHYLPHENIDATE CR should not be used to treat severe exogenous or endogenous depression.

Reproductive Health: Female and Male Potential

• Function

  Priapism: Prolonged and painful erections requiring immediate medical attention (sometimes including surgical intervention), have been reported with methylphenidate products, in both pediatric and adult patients (see 8.5 Post-Market Adverse Reactions). Priapism can develop after some time on methylphenidate, often subsequent to an increase in dose. Priapism has also appeared during a period of methylphenidate withdrawal (drug holidays or during discontinuation). Patients who develop abnormally sustained erections or frequent and painful erections should seek immediate medical attention.

• Teratogenic Risk:

  Methylphenidate hydrochloride has been shown to have teratogenic effects in rabbits when given in doses of 200 mg/kg/day, which is approximately 100 times and 40 times the maximum recommended human dose on a mg/kg and mg/m² basis, respectively (see 16 NON-CLINICAL TOXICOLOGY, Reproductive and Developmental Toxicology).

Vascular

Peripheral Vasculopathy, including Raynaud’s Phenomenon

Stimulants used to treat ADHD, such as methylphenidate hydrochloride controlled-release capsules, are associated with peripheral vasculopathy, including Raynaud’s phenomenon. Signs and symptoms are usually intermittent and mild; however, very rare sequelae include digital ulceration and/or soft tissue breakdown. Effects of peripheral vasculopathy, including Raynaud’s phenomenon, were observed in post-marketing reports at different times and at therapeutic doses in all age groups throughout the course of treatment. Signs and symptoms generally improve after reduction in dose or discontinuation of drug. Careful observation for digital changes is necessary during treatment with ADHD stimulants. Further clinical evaluation (e.g., rheumatology referral) may be appropriate for certain patients.

7.1 Special Populations

7.1.1 Pregnant Women

Studies to establish safe use of methylphenidate in pregnant women have not been conducted. Therefore, APO-METHYLPHENIDATE CR should not be given to pregnant women unless the potential benefit outweighs the risk to the fetus.

7.1.2 Breast-feeding

Case reports showed that methylphenidate was distributed into breast milk reaching a milk-to- plasma ratio of approximately 2.5 (see 10.3 Pharmacokinetics, Elimination). A risk to the suckling child cannot be excluded hence precaution should be exercised because many drugs can be excreted in human milk. A decision should be made whether to abstain from breast- feeding or to abstain from APO-METHYLPHENIDATE CR therapy, taking into account the benefit of breast-feeding to the child and the benefit of therapy to the woman.

There is one case report of an infant who experienced an unspecified decrease in weight during the period of exposure but recovered and gained weight after the mother discontinued treatment with methylphenidate.

7.1.3 Pediatrics

Pediatrics (<6 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use in patients under 6 years of age

(see 1.1 Pediatrics).

7.1.4 Geriatrics

Geriatrics (>65 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for geriatric use (see 1.2 Geriatrics).

8 ADVERSE REACTIONS

8.1 Adverse Reaction Overview

The safety and efficacy of methylphenidate hydrochloride controlled-release capsules was investigated in adults (>18 years old) and children (6 to 18 years old). The most common adverse events reported in clinical trials in 10% of patients or greater were headache, decreased appetite, nervousness, insomnia, nausea, anxiety, dry mouth, somnolence and affect lability. Four serious adverse events, judged to be not related to study medication, were reported in children during clinical trials or compassionate use with methylphenidate hydrochloride controlled-release capsules: adjustment disorder with mixed disturbance of emotion and conduct (n=1), injury - induced migraine headache (n=1), appendicitis (n=1) and conversion disorder (n=1).

Although not reported during clinical trials with methylphenidate hydrochloride controlled-release capsules, sudden death has occurred in pediatric patients with structural cardiac abnormalities and other serious cardiac problems taking CNS stimulants at recommended doses for ADHD and sudden death, stroke and myocardial infarction have occurred in adults treated with CNS stimulants at recommended doses. Although not reported during clinical trials with methylphenidate hydrochloride controlled-release capsules, CNS stimulants have a high potential for abuse and dependence (see 7 WARNINGS AND PRECAUTIONS, Dependence/Tolerance).

8.2 Clinical Trial Adverse Reactions

Clinical trials are conducted under very specific conditions. The adverse reaction rates observed in the clinical trials, therefore, may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse reaction information from clinical trials may be useful in identifying and approximating rates of adverse drug reactions in real-world use.

Adverse events in adults with ADHD were evaluated in a Canadian randomized controlled trial, in comparison with placebo. A summary of adverse events occurring at an incidence of 1% or more is given in Table 2, which includes all events, whether considered by the clinical investigator to be related to the study drug or not.

Table 2 – Adverse Events^a with a ≥1% Incidence in Adult Patients (>18 years of age) with ADHD Treated with Methylphenidate Hydrochloride Controlled-Release Capsules

^a Events are listed regardless of the causality assessment by the clinical investigator.

8.2.1 Clinical Trial Adverse Reactions – Pediatrics

Adverse events in children aged 6 to 11 and adolescents aged 12 to 18 with ADHD were evaluated in two Canadian randomized controlled clinical trials of methylphenidate hydrochloride controlled-release capsules in comparison with placebo and immediate release methylphenidate. Table 3 and Table 4 list all adverse events occurring at an incidence of 1% or more, from both studies, in children (6 to 11 years of age) and adolescents (12 to 18 years of age), whether considered by the clinical investigator to be related to the study drug or not.

Table 3 – Adverse Events^a with a ≥1% Incidence in Children (6 to 11 years of age) with ADHD Treated with Methylphenidate Hydrochloride Controlled-Release Capsules

^a Events are listed regardless of the causality assessment by the clinical investigator.

Table 4 – Adverse Events^a with a ≥1% Incidence in Adolescents (12 to 18 years of age) with ADHD Treated with Methylphenidate Hydrochloride Controlled-Release Capsules

^a Events are listed regardless of the causality assessment by the clinical investigator.

8.3 Less Common Clinical Trial Adverse Reactions

There were no adverse events reported to have occurred in <1% of the adults in the methylphenidate hydrochloride controlled-release capsules clinical trial.

8.3.1 Less Common Clinical Trial Adverse Reactions – Pediatrics

There were no adverse events reported to have occurred in <1% of the children (6 to 11 years of age) in the methylphenidate hydrochloride controlled-release capsules clinical trials.

There were no adverse events reported to have occurred in <1% of the adolescents (12 to 17 years of age) in the methylphenidate hydrochloride controlled-release capsules clinical trials.

Two one-week, placebo-controlled clinical studies have been conducted post-market with methylphenidate hydrochloride controlled-release capsules (10 to 40 mg) in pediatric patients; one in children aged 6 to 12 years, and one in children and adolescents aged 6 to 17 years. The two studies evaluated a total of 256 patients with ADHD. From these studies, the following events have also been reported with methylphenidate hydrochloride controlled-release capsules:

Investigations: blood creatine phosphokinase increased, electrocardiogram QT prolonged

Metabolism and Nutrition Disorders: decreased appetite

Musculoskeletal and Connective Tissue Disorders: musculoskeletal stiffness

Nervous System Disorders: lethargy

Psychiatric Disorders: crying, irritability, oppositional defiant disorder, psychomotor hyperactivity, tearfulness

8.5 Post-Market Adverse Reactions

• Suicidal Behaviour and Ideation

  There have been post-marketing reports of suicide-related events, including completed suicide, suicide attempt, and suicidal ideation in patients treated with ADHD drugs. In some of these reports, comorbid conditions may have contributed to the event (see 7 WARNINGS AND PRECAUTIONS, Psychiatric, Suicidal Behaviour and Ideation).

• Adverse Events Reported with Methylphenidate Hydrochloride Products

  Nervousness and insomnia are the most common adverse reactions reported with methylphenidate products. Other reactions include hypersensitivity (including skin rash, urticaria, fever, arthralgia, exfoliative dermatitis, erythema multiforme with histopathological findings of necrotizing vasculitis, and thrombocytopenic purpura); acute hepatic failure; abdominal pain; anemia; angina; anorexia; blood pressure and pulse changes, both up and down; bradycardia; drowsiness; headache; leukopenia; nausea; pancreatitis; Stevens-Johnson Syndrome; sudden cardiac death; tachycardia; weight loss during prolonged therapy. There have been rare reports of Tourette’s syndrome. Toxic psychosis has also been reported.

  The following events have also been reported with methylphenidate products, including:

  Alopecia, angioedema, blurred vision, convulsions, dizziness, dyskinesia, erythema, flushing, hallucinations, incontinence, mydriasis, psychotic disorder, tremor, trismus, Raynaud’s phenomenon, epistaxis, anaphylactic reaction, photosensitivity reaction, skin discoloration, skin odor abnormal, muscle cramps, choreoathetoid movements, presyncope, somnambulism, dysphemia, euphoric mood, visual disturbance, difficulties in accommodation, vasodilation, cardiac arrhythmias, ECG QT prolongation, change in sustained attention, dermatillomania, hallucination, impulsive behaviour, logorrhea, obsessive–compulsive disorder, onychophagia, self-injurious behaviour, thinking abnormal, aplastic anemia, pancytopenia, leucopenia, thrombocytopenia, hypoglycemia, rhabdomyolysis, transient depressed mood and priapism.

  Although a definite causal relationship has not been established, the following have been reported in patients taking methylphenidate products: instances of abnormal liver function (e.g., ranging from transaminase elevation to hepatic coma); isolated cases of cerebral arteritis and/or occlusion and gynecomastia. Very rare reports of neuroleptic malignant syndrome (NMS) have been received, and in most of these, patients were concurrently receiving therapies associated with NMS. In a single report, a ten-year-old boy who had been taking methylphenidate for approximately 18 months experienced an NMS-like event within 45 minutes of ingesting his first dose of venlafaxine. It is uncertain whether this case represented a drug-drug interaction, a response to either drug alone, or some other cause.

9 DRUG INTERACTIONS

9.1 Serious Drug Interactions

Serious Drug Interactions

• Co-Administration of Monoamine Oxidase Inhibitors (MAOIs); see 2

  CONTRAINDICATIONS; 9.4 Drug-Drug Interactions, Monoamine Oxidase Inhibitors

• Co-Administration of Clonidine; see 9.4 Drug-Drug Interactions, Clonidine

9.2 Drug Interactions Overview

Because of possible increases in blood pressure and heart rate, APO-METHYLPHENIDATE CR should be used cautiously with drugs with similar pharmacological actions.

9.3 Drug-Behavioural Interactions

• Alcohol

  Patients undergoing APO-METHYLPHENIDATE CR therapy should be advised to avoid alcohol during treatment (see 7 WARNING AND PRECAUTIONS, Dependence/Tolerance).

  Alcohol may exacerbate the CNS adverse effect of APO-METHYLPHENIDATE CR. Alcohol may induce the production of methylphenidate. The amount of methylphenidate production is proportional to the blood alcohol concentration.

9.4 Drug-Drug Interactions

• Anti-hypertensive Drugs

  Methylphenidate may decrease the effectiveness of drugs used to treat hypertension (see 7 WARNINGS AND PRECAUTIONS, Cardiovascular).

• Antipsychotics

  Because a predominant action of methylphenidate is to increase extracellular dopamine levels, APO-METHYLPHENIDATE CR may be associated with pharmacodynamic interactions when co- administered with some antipsychotics. Caution is warranted in patients receiving both APO-METHYLPHENIDATE CR and an antipsychotic, as extrapyramidal symptoms could emerge when these drugs are administered concomitantly or when adjusting the dosage of one or both drugs.

• Clonidine

  Serious adverse events including sudden death have been reported in concomitant use with Clonidine. In these cases, no causality for the combination could be established because of insufficient data.

• Vasopressor Agents

  Because of possible increases in blood pressure and heart rate, APO-METHYLPHENIDATE CR should be used cautiously with drugs with similar actions.

• Inhibition of Drug Metabolism by Methylphenidate

  Human pharmacologic studies have shown that methylphenidate may inhibit the metabolism of:

  • coumarin anticoagulants (e.g., warfarin),
  • anticonvulsants (e.g., phenobarbital, phenytoin, primidone)
  • some antidepressants (tricyclics and selective serotonin reuptake inhibitors).

Downward dose adjustment of these drugs may be required when given concomitantly with methylphenidate. It may be necessary to adjust the dosage and monitor plasma drug concentrations (or, in the case of coumarin, coagulation times) when initiating or discontinuing concomitant methylphenidate.

• Monoamine Oxidase Inhibitors (MAOIs)

  Methylphenidate is contraindicated during treatment with monoamine oxidase inhibitors, and also within a minimum of 14 days following discontinuation of a monoamine oxidase inhibitor (hypertensive crises may result). The same precautions apply to APO-METHYLPHENIDATE CR (see 2 CONTRAINDICATIONS).

• Serotonergic Drugs

  The concomitant use of methylphenidate and serotonergic drugs is not recommended as this may lead to the development of serotonin syndrome on rare occasions. This includes serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), monoamine oxidase inhibitors (MAOIs), serotonin 5-HT1 receptor agonists (triptans), and 5-HT3 receptor antagonist antiemetics. If concomitant treatment with APO-METHYLPHENIDATE CR and other serotonergic agents is clinically warranted, careful observation of the patient is advised (see 7 WARNINGS AND PRECAUTIONS, Neurologic, Serotonin Toxicity / Serotonin syndrome). If serotonin toxicity is suspected, APO-METHYLPHENIDATE CR (and serotonergic drugs) must be immediately discontinued and appropriate treatment instituted.

9.5 Drug-Food Interactions

A pharmacokinetic study demonstrated no significant differences in the rate and extent of absorption in patients under fed or fasted conditions (see 10.3 Pharmacokinetics, Absorption). APO-METHYLPHENIDATE CR may be taken with or without food. However, concomitant food intake has variable effects on methylphenidate exposure. Thus, a regular morning routine should be established, with regard to the content and timing of meals, in order to ensure consistent efficacy and safety (see 4.4 Administration).

9.6 Drug-Herb Interactions

Interactions with herbal products have not been established.

9.7 Drug-Laboratory Test Interactions

Interactions with laboratory tests have not been established.

10 CLINICAL PHARMACOLOGY

10.1 Mechanism of Action

Methylphenidate is a central nervous system (CNS) stimulant. The mode of action of stimulants in Attention-Deficit Hyperactivity Disorder (ADHD) is not completely understood, but they are thought to act primarily through indirect mechanisms, such as release of dopamine and norepinephrine from neuronal pools, and inhibition of neurotransmitter reuptake.

There is some evidence suggesting that the mechanism whereby methylphenidate produces its mental and behavioural effects in children is related to a dose-dependent blockade of the dopamine transporter and an increase in extracellular dopamine. While the evidence regarding how these effects relate to the condition of the CNS is not conclusive, it is likely that an increase in dopamine transporter activity is part of the underlying mechanistic basis of ADHD.

The pharmacological properties of methylphenidate are similar to those of the amphetamines. However, in contrast to amphetamines, methylphenidate is a mild CNS stimulant with more prominent effects on mental than motor activities.

Methylphenidate increases extracellular concentrations of dopamine and norepinephrine by inhibiting their neuronal reuptake and is also an inhibitor of monoamine oxidase.

The behavioural and cognitive symptoms in ADHD and their response to stimulants are considered to reflect activity of dopaminergic and noradrenergic systems. Dopamine transporter binding sites are increased in the brains of ADHD patients and there is evidence for a genetic basis for this finding. Methylphenidate has been shown to both increase extracellular dopamine in the human brain and to reduce the number of dopamine transporter binding sites in patients with ADHD.

10.2 Pharmacodynamics

Methylphenidate exists as erythro and threo isomers but only the threo isomer possesses motor stimulant effects. Since both isomers inhibit monoamine oxidase, this suggests that this activity is not a primary mechanism of action of the dl-threo isomer when used clinically in ADHD.

dl-threo methylphenidate displays enantioselective pharmacokinetics. After administration of dl-methylphenidate, plasma concentrations of d-methylphenidate are greater than those of l-methylphenidate, due to preferential pre-systemic metabolism of the l-enantiomer to l- ritalinic acid. In addition, presence of the d-enantiomer inhibits the conversion of the l - enantiomer to ritalinic acid.

APO-METHYLPHENIDATE CR is a once-daily, modified-release methylphenidate preparation which utilizes multilayer release coated pellets, where 40% of the dose is provided as an immediate release and 60% is provided through a gradual release. Data from clinical trials suggests that once-daily administration of methylphenidate hydrochloride controlled-release capsules, in the morning, improves behavioral and cognitive measures in adults and children over 6 years of age, with improvements observed within 1 hour and persisting into the evening (see 14.1 Efficacy and Safety studies, Attention-Deficit Hyperactivity Disorder (ADHD)).

10.3 Pharmacokinetics

Absorption:

Methylphenidate is rapidly and extensively absorbed following oral administration - with peak blood levels obtained in 1 to 3 hours.

In a single dose study in healthy adult volunteer subjects, methylphenidate hydrochloride controlled-release capsules, 20 mg was fully bioavailable, relative to two separate 10 mg doses of an immediate-release reference formulation, under both fasted and fed conditions (relative AUC_t 96% and 107%, respectively). Relative partial AUC was 73.67% and 97.14% for time segments 0 to 3 hours fasted and 0 to 4 hours fed, respectively. In a single dose study in young children (6 to 12 years) with ADHD, methylphenidate hydrochloride controlled-release capsules, when given at a dose equal to the patient’s pre-study methylphenidate dose (mean dose 38.6 mg), following a child’s typical breakfast, was fully bioavailable relative to the same daily dose of immediate - release methylphenidate given as two separate doses (relative AUC_t 101%). Relative partial AUC was 93.69% for the 0 to 4 hour time segment.

Methylphenidate hydrochloride controlled-release capsules were designed to be an alternative to separate doses of immediate release methylphenidate by providing a biphasic plasma concentration time profile when given as a single dose. The rate of increase in plasma methylphenidate concentration with the controlled release formulation was similar to that with the immediate-release formulation. In adults the initial peak concentration occurred at 1.7 hours post-dose for methylphenidate hydrochloride controlled-release capsules and at 1.8 hours post-dose for the immediate-release formulation, when given under fasting conditions, and at 2.0 hours post-dose and 2.5 hours post-dose, respectively, when given with food. The initial maximum concentration (C_max) achieved with the controlled release formulation was 76% (fasted) and 84% (fed) of that of immediate-release methylphenidate. In young children, being treated for ADHD with methylphenidate, the initial peak concentration occurred at 2.6 hours post-dose for methylphenidate hydrochloride controlled-release capsules and at 2.1 hours post-dose for the immediate-release formulation, when given at doses equal to the children’s pre-study maintenance doses. The initial maximum concentration achieved with the controlled release formulation was 79% of that of immediate - release methylphenidate.

Distribution:

In blood, methylphenidate and its metabolites are distributed between plasma (57%) and erythrocytes (43%). Methylphenidate and its metabolites exhibit low plasma protein binding (approximately 15%).

Metabolism:

The primary route of metabolism for methylphenidate is de-esterification to the inactive metabolite, ritalinic acid (α-phenyl-2-piperidine acetic acid), which represents 60 to 81% of the administered dose, and 6-oxy-α-phenyl-2-piperidineacetic acid (9 to 12% of the administered dose). Unchanged drug accounts for less than 1% of the administered dose. First pass metabolism results in an absolute bioavailability of 30% with large inter-individual differences (11 to 52%).

Elimination:

Methylphenidate is excreted almost entirely in the urine. After oral dosing of radiolabeled methylphenidate in humans, about 90% of the radioactivity was recovered in urine. The main urinary metabolite was ritalinic acid, accounting for approximately 80% of the dose (see 10.3 Pharmacokinetics, Special Populations and Conditions, Renal Insufficiency).

Methylphenidate is eliminated from plasma with a mean half-life of 2.4 hours in children and 2.1 hours in adults. The apparent systemic clearance, for a 0.3 mg/kg dose, is 10.2 and 10.5 L/h/kg in children and adults, respectively. These data indicate that the pharmacokinetic behavior of methylphenidate in hyperactive children is similar to that in normal adults. The apparent distribution volume of methylphenidate in children is approximately 20 L/kg, with substantial variability (11 to 33 L/kg).

Special Populations and Conditions

• Pediatrics: The pharmacokinetics of methylphenidate hydrochloride controlled-release capsules has not been studied in children less than 6 years of age, and APO-METHYLPHENIDATE CR should not be used in this patient population.
• Geriatrics: There is no data available for the use of methylphenidate hydrochloride controlled-release capsules in patients over 65 years of age.
• Pregnancy and Breast-feeding: Methylphenidate excretion into breast milk has been noted in two case reports, where the calculated relative infant dose was ≤0.2% of the weight adjusted maternal dose.
• Hepatic Insufficiency: Methylphenidate hydrochloride controlled-release capsules has not been studied in patients with hepatic insufficiency.
• Renal Insufficiency: There is limited experience with the use of methylphenidate in patients with renal insufficiency. Since renal clearance is not a significant contributor to methylphenidate elimination, and ritalinic acid is an inactive metabolite, renal insufficiency is expected to have little effect on the pharmacokinetics of APO-METHYLPHENIDATE CR.

11 STORAGE, STABILITY AND DISPOSAL

Store in a cool, dry place between 15°C - 30°C. Protect from moisture.

Keep APO-METHYLPHENIDATE CR in a safe place out of sight and reach of children and pets.

12 SPECIAL HANDLING INSTRUCTIONS

There are no special handling instructions.

PART II: SCIENTIFIC INFORMATION

13 PHARMACEUTICAL INFORMATION

Drug Substance

Proper name: methylphenidate hydrochloride

Chemical name: Methyl α-phenyl-2-piperidineacetate hydrochloride

Molecular formula and molecular mass: C₁₄H₁₉NO₂. HCl, 269.77 g/mol

Structural formula:

Physicochemical properties: Methylphenidate hydrochloride is a white, odourless, fine, crystalline powder. It is freely soluble in water and in methanol, soluble in alcohol, and slightly soluble in chloroform and in acetone. It has a pKa of 8.9 and a melting point between 224°C and 226°C.

14 CLINICAL TRIALS

14.1 Efficacy and Safety studies

Trial Design and Study Demographics

Methylphenidate hydrochloride controlled-release capsules were studied in four double-blind, active- and placebo-controlled studies involving children (>6 years of age) and adults, who met the American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Illness, 4th edition (DSM-IV) criteria for ADHD.

Table 5 - Summary of Patient Demographics for Clinical Trials in Children ≥6 Years of Age with ADHD

^a The doses of methylphenidate hydrochloride controlled-release capsules and IR Methylphenidate were titrated in each phase of the study and the final mean doses were very similar (32.0 ± 8.4 mg and 32.5 ± 8.6 mg/day respectively).

^b Represents titration to optimal effect (one to three weeks), followed by a one-week stable dose period, and then two weeks of treatment on that dose; crossover to other treatment with titration (one to three weeks) followed by two weeks treatment.

^c Patients were crossed-over between methylphenidate hydrochloride controlled-release capsules and IR Methylphenidate at the same total daily dose (mean 31.2 ± 11.7 mg) which was based on their pre-study methylphenidate dose (or on body weight, if not receiving methylphenidate).

^d Represents 1-week on each treatment.

^e Patients were crossed-over between methylphenidate hydrochloride controlled-release capsules and placebo at the same total daily dose, based on titration to optimal effect.

^f Represents titration to optimal effect (two to four weeks), followed by a one-week double-blind treatment at optimal dose on active or placebo culminating in a 12-hour classroom assessment, and another one-week double-blind treatment at optimal dose on the remaining treatment (active or placebo), culminating in a second 12-hour classroom assessment.

*18 enrolled, 17 evaluable

Table 6 – Summary of Patient Demographics for Clinical Trials in Adults >18 Years of Age with ADHD

^a Represents titration to optimal effect (one to three weeks), followed by a one-week stable dose period, and then two weeks of treatment on that dose; crossover to other treatment with titration (one to three weeks) followed by two weeks treatment.

14.2 Study Results

Table 7 – Results of Study 1 (022-004) in Children ≥6 Years of Age with ADHD

Table 8– Results of Study 2 (022-005) in Children ≥6 Years of Age with ADHD

^a Methylphenidate hydrochloride controlled-release capsules was given as a single morning dose, while immediate-release methylphenidate was given at the same daily dose, in equally divided doses, in the morning and at lunchtime.

^b Improvements, relative to placebo, were noted within 1 hour on Methylphenidate hydrochloride controlled-release capsules and persisted into the early evening.

Table 9 – Results of Study 3 (RP-BP-EF001) in Children ≥6 and ≤12 Years of Age with ADHD*

*Lower SKAMP total scores indicate improvement

^a Methylphenidate hydrochloride controlled-release capsules was administered as a single, optimized, morning dose.

Table 10 – Results of Study 4 (022-008) in Adults ≥18 Years of Age with ADHD

^a Methylphenidate hydrochloride controlled-release capsules was administered as a single, optimized, morning dose.

14.3 Comparative Bioavailability Studies

A randomized, single-dose, two-way crossover comparative bioavailability study of APO-METHYLPHENIDATE CR 80 mg capsules (Apotex Inc.) with BIPHENTIN® 80 mg capsules (Purdue Pharma) was conducted in healthy, adult, male and female subjects under fasting conditions. Comparative bioavailability data from 23 subjects that were included in the statistical analysis are presented in the following table:

SUMMARY TABLE OF THE COMPARATIVE BIOAVAILABILITY DATA

¹ APO-METHYLPHENIDATE CR (methylphenidate hydrochloride) controlled release capsules, 80 mg (Apotex Inc.)

² BIPHENTIN^® (methylphenidate hydrochloride) controlled release capsules, 80 mg (Purdue Pharma, Canada)

³ Expressed as median (range) only

⁴ Expressed as arithmetic mean (CV%) only

A randomized, single-dose, two-way crossover comparative bioavailability study of APO-METHYLPHENIDATE CR 80 mg capsules (Apotex Inc.) with BIPHENTIN® 80 mg capsules (Purdue Pharma) was conducted in healthy, adult, male and female subjects under fed conditions. Comparative bioavailability data from 26 subjects that were included in the statistical analysis are presented in the following table:

SUMMARY TABLE OF THE COMPARATIVE BIOAVAILABILITY DATA

¹ APO-METHYLPHENIDATE CR (methylphenidate hydrochloride) controlled release capsules, 80 mg (Apotex Inc.)

² BIPHENTIN® (methylphenidate hydrochloride) controlled release capsules, 80 mg (Purdue Pharma, Canada)

³ Expressed as median (range) only

⁴ Expressed as arithmetic mean (CV%) only

15 MICROBIOLOGY

No microbiological information is required for this product.

16 NON-CLINICAL TOXICOLOGY

Genotoxicity: Methylphenidate was not mutagenic in the Salmonella assay system. Epidemiology studies of methylphenidate have found no evidence of a carcinogenic effect in humans.

Carcinogenicity: Toxicology and carcinogenesis studies with methylphenidate hydrochloride were performed in rats and mice. Methylphenidate was administered for 2 years at doses of 0, 100, 500 or 1,000 ppm in the feed of rats and 0, 50, 250 and 500 ppm to mice. The average amount of methylphenidate consumed per day was estimated to be 4 to 47 mg/kg/day for rats and 5 to 67 mg/kg/day for mice. An increase of benign tumours of the liver, and increased liver weights, were observed in mice at the high dose. Increased incidences of neoplasms were not seen in the rats.

Reproductive and Developmental Toxicology: A reproductive toxicity study in mice demonstrated that doses of 18, 75 and 160 mg/kg/day did not produce any changes in reproductive end points, despite changes in liver weights and male body weights.

In animal studies, no teratogenic effects were seen in rats when given at a dose of 75 mg/kg/day, which are 62.5 and 13.5 times the maximum recommended human dose on a mg/kg and mg/m² basis respectively. In another study, however, methylphenidate was shown to be teratogenic in rabbits when given at a dose of 200 mg/kg/day, which is approximately 100 times and 40 times higher than the maximum recommended human dose on a mg/kg and mg/m² basis, respectively.

17 SUPPORTING PRODUCT MONOGRAPHS

1. 1. BIPHENTIN® (Controlled-Release Capsules, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg and 80 mg), Submission Control 272109, Product Monograph, Elvium Life Sciences. (JAN 10, 2025)